NYU Langone Health

First Mice Engineered to Survive COVID-19 Like Young, Healthy Humans

Retrieved on: 
Wednesday, November 1, 2023

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

Key Points: 
  • NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.
  • The mice with this genetic change developed symptoms similar to young humans infected with the virus causing COVID-19, instead of dying upon infection as had occurred with prior mouse models.
  • "This has been a major missing piece in efforts to develop new drugs against this virus."
  • Boeke also receives consulting fees and royalties from OpenTrons, and holds equity in the company.

Jona, a Personalized Health Company Using AI to Analyze the Gut Microbiome, Launches with $5M in Funding

Retrieved on: 
Wednesday, November 1, 2023

With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."

Key Points: 
  • With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."
  • Jona's platform aims to equip these individuals with the latest scientific knowledge to discover root causes and develop effective treatment plans.
  • "Launching this company is a culmination of my lived experiences and a lifelong career in artificial intelligence and healthcare."
  • The first product is an easy at-home microbiome profiling kit that sequences the microbes in an individual's gut microbiome.

MetroPlusHealth Opens Enrollment for its Gold Health Plan

Retrieved on: 
Wednesday, November 1, 2023

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- MetroPlusHealth, New York City's high-quality and affordable health plan, released the findings of its third annual MetroPlusHealth Healthy People Study today, which measures national and NYC consumers' attitudes towards their health care and what they care about most as it relates to cost, quality of care, and their health insurance plans.

Key Points: 
  • Talya Schwartz, MD, President, & CEO of MetroPlusHealth, added, "Our Gold Plan embodies our commitment to providing top-tier health care to New York City employees, ensuring it is not only high-quality but also easily accessible.
  • With MetroPlusHealth Gold Plan, all members get unlimited mental health visits, with $0 copays.
  • The Gold Health Plan is offered exclusively to all New York City (NYC) employees, non-Medicare eligible retirees, their spouses or qualified domestic partners, and eligible dependents.
  • MetroPlusHealth will kick off its Gold Plan enrollment with a "Champion Gold Room Celebration" on November 2, 2023, from 10:00 AM to 2:00 PM, at 50 Water Street.

Turtle Announces New Leadership for a New Century: Jayne Millard and Luis Valls Named Co-CEOs

Retrieved on: 
Wednesday, November 1, 2023

CLARK, N.J., Nov. 1, 2023 /PRNewswire/ -- As part of ambitious plans for transformational growth in its second century of innovation, the Board of Directors of Turtle, one of the country's largest independent electrical and industrial distributors, has announced that effective today, Jayne Millard, Executive Chairman of the Board and fourth-generation family leader, and Luis Valls, President of Turtle's Electrical Division, will head the company as Co-CEOs. With a core mission of accelerating the transition to clean, sustainable energy — Rethinking Energy and Advancing Tomorrow — together they bring a unique perspective and diversity of thought combining Millard's strategic vision and Valls' industry-leading engineering expertise. 

Key Points: 
  • "This succession plan involved the Board of Directors, Kathleen and Luis," explains Millard.
  • Toward this most profound challenge of our time, I am eager to take an active leadership role as Co-CEO while maintaining strategic leadership as Executive Chair of the Turtle Board."
  • Millard is the third generation of women to lead Turtle, a 100-year-old, family- and woman-owned enterprise co-founded by her great-grandfather in 1923.
  • Growing up in the business, Millard held positions of increasing responsibility before being named CEO in 2010 and Executive Chairman in 2016.

NYU Langone Receives $9.8 Million to Advance Pediatric Medicine

Retrieved on: 
Monday, October 30, 2023

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- The Department of Pediatrics at NYU Langone Health has received $9.8 million from NYU Langone trustee Trudy Elbaum Gottesman and Robert W. Gottesman, founding donors of Sala Institute for Child and Family Centered Care, which has profoundly influenced excellence in clinical care across Hassenfeld Children's Hospital at NYU Langone since 2013.

Key Points: 
  • NEW YORK, Oct. 30, 2023 /PRNewswire/ -- The Department of Pediatrics at NYU Langone Health has received $9.8 million from NYU Langone trustee Trudy Elbaum Gottesman and Robert W. Gottesman, founding donors of Sala Institute for Child and Family Centered Care , which has profoundly influenced excellence in clinical care across Hassenfeld Children's Hospital at NYU Langone since 2013.
  • "We are proud to support innovations in pediatric research and career growth of physician–scientists," said Trudy Elbaum Gottesman.
  • "Providing exceptional care means understanding the unique needs of the patients we see at NYU Langone Health—and there is often no patient more vulnerable, or more resilient, than a child," said Robert I. Grossman, MD , dean of NYU Grossman School of Medicine and CEO of NYU Langone Health.
  • "This fund will help us continue to provide top-notch training to our pediatric fellows, ensuring more pediatric physicians have deep experience in child- and family-centered care."

Brain Injury Expert Says Important Changes Still Needed to Law Defining Death Despite Reform Pause

Retrieved on: 
Thursday, October 26, 2023

The recently announced pause by the Uniform Law Commission, which is spearheading revisions, is disappointing, the expert notes, but should not permanently stall practical fixes to longstanding problems with the Death Act.

Key Points: 
  • The recently announced pause by the Uniform Law Commission, which is spearheading revisions, is disappointing, the expert notes, but should not permanently stall practical fixes to longstanding problems with the Death Act.
  • Lewis says her survey results showed that 34 organizations (83%) favored revisions to the Death Act.
  • Uniform Determination of Death Act, which defined death as either the irreversible cessation of all brain or cardiopulmonary functions.
  • However, such loss of hormone function is not needed to be declared dead by brain criteria using current medical standards.

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Retrieved on: 
Sunday, October 22, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology (ESMO) Congress in Madrid, Spain.

Key Points: 
  • Advanced endometrial cancer is the only gynecologic malignancy with increasing incidence and mortality in both the US and Europe1.
  • Estimated incidence in the EU: 92,746 pts with 23,047 deaths (2022)2 and in the US: 66,000 pts with 13,030 deaths (2023)3.
  • “We are pleased to have the opportunity to present these encouraging early data at ESMO this year,” said Anne Borgman, M.D., Sutro’s Chief Medical Officer.
  • Consistent with previous reported luvelta safety results, the most common adverse event was neutropenia; no new safety signals were observed
    *2: European Cancer Information System (ECIS).

Two NYU Langone Health Faculty Elected to National Academy of Medicine

Retrieved on: 
Tuesday, October 24, 2023

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Céline R. Gounder, MD, ScM , and Robert Montgomery, MD, DPhil , two innovators at NYU Langone, have been elected to the National Academy of Medicine, one of the highest honors in their field.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Céline R. Gounder, MD, ScM , and Robert Montgomery, MD, DPhil , two innovators at NYU Langone, have been elected to the National Academy of Medicine, one of the highest honors in their field.
  • In a statement, the academy recognized her "for being one of the world's leading experts in communication about science, medicine, and public health.
  • Dr. Montgomery, is the H. Leon Pachter, MD, Professor of Surgery, chair of the Department of Surgery at NYU Grossman School of Medicine, and director of the NYU Langone Transplant Institute .
  • The academy addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors.

The Lupus Research Alliance Walk with Us to Cure Lupus Takes Off at the Intrepid Museum

Retrieved on: 
Friday, October 20, 2023

NEW YORK, Oct. 20, 2023 /PRNewswire/ -- Thousands of supporters will join together Saturday, October 21 at the Intrepid Museum (formerly called the Intrepid Sea, Air and Space Museum) to celebrate the 20th Anniversary of the Lupus Research Alliance (LRA) 2023 New York City Walk with Us to Cure Lupus.

Key Points: 
  • NEW YORK, Oct. 20, 2023 /PRNewswire/ -- Thousands of supporters will join together Saturday, October 21 at the Intrepid Museum (formerly called the Intrepid Sea, Air and Space Museum) to celebrate the 20th Anniversary of the Lupus Research Alliance (LRA) 2023 New York City Walk with Us to Cure Lupus.
  • That number is still climbing as Walkers continue to fundraise for lupus research.
  • Because the LRA's Board of Directors covers all administrative and fundraising costs, 100 percent of these donations go directly to lupus research programs.
  • Joining the Walk with Us to Cure Lupus program to raise funds is just one way to contribute to the lupus cause.

Immuno-Oncology360º Announces 2024 Keynotes and Featured Speakers for the 10th Annual NYC Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • The Conference Forum announced the IO360º Summit's 2024 keynotes and featured speakers for its 10th annual conference.
  • NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.
  • The IO360° 2024 keynotes include:
    Genentech's Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
  • "The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space.